share_log

Jones Trading Initiates Coverage On Intellia Therapeutics With Buy Rating, Announces Price Target of $41

Benzinga ·  Sep 18 04:57  · Ratings

Jones Trading analyst Debanjana Chatterjee initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Buy rating and announces Price Target of $41.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment